Iota-carrageenan as an antiviral treatment for the common cold by Eccles, Ronald
1874-3579/20 Send Orders for Reprints to reprints@benthamscience.net
9
DOI: 10.2174/1874357902014010009, 2020, 14, 9-15
The Open Virology Journal
Content list available at: https://openvirologyjournal.com
LETTER
Iota-Carrageenan as an Antiviral Treatment for the Common Cold
Ronald Eccles1,*
1Cardiff School of Biosciences, Cardiff University, Cardiff, UK
Abstract:
Introduction:
The common cold syndrome of acute upper respiratory tract viral infection is the most common disease among mankind and is an extremely
common illness in children. There is a great need for a safe and effective antiviral treatment with minimal side effects. The challenge in developing
a treatment is the numerous and varied respiratory viruses that cause this common illness and the need for a treatment with good tolerability and
safety.
Explanation:
All respiratory viruses must reach the cell surface by passing through respiratory fluid and mucus, and this common feature may allow for the
development of antivirals that capture viruses during this transit.
This article discusses how large polyanionic molecules such as iota-carrageenan may trap positively charged respiratory viruses. Iota-carrageenan
is  a  large  polysaccharide  molecule  which  is  neither  absorbed  from  the  respiratory  tract  nor  metabolised.  It,  therefore,  does  not  have  any
pharmacological properties. Iota-carrageenan nasal spray has been shown to reduce the titres of respiratory viruses and to reduce the severity of
symptoms in placebo-controlled clinical trials, including children and adults. The results of four clinical trials are presented.
Conclusion:
Iota-carrageenan is a good candidate as a safe and effective non-specific antiviral treatment for common cold, and more research is justified on
polyanionic molecules like carrageenans as antivirals.
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1. INTRODUCTION
Acute  upper  respiratory  tract  viral  infections  such  as
common cold are probably the most common viral diseases of
mankind. Common cold is caused by a wide range of viruses
such  as  rhinoviruses,  coronaviruses,  influenza  viruses,
Respiratory  Syncytial  Viruses  (RSV),  parainfluenza  viruses,
adenoviruses, enteroviruses, metapneumoviruses and unknown
viruses which may be responsible for 20-30% of infections [1].
With such a wide range of viruses responsible for the common
cold syndrome, it is not surprising that there is a great unmet
need for a safe and well-tolerated antiviral  treatment for this
most common disease.
A major issue in developing an antiviral treatment for the
common cold is that focussing on one group of viruses such as
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rhinoviruses, which may on occasion account for at least 50%
of colds [2], means that the treatment would only be effective
in treating 50% of colds, and this would not be acceptable as a
freely  available  treatment  to  the  general  public.  Antiviral
treatments  aimed  at  blocking  the  viral  receptor  or  host  cell
receptor are unlikely to be of benefit in treating common cold
as they are developed to act specifically on only one group of
viruses.
The  common  cold,  therefore,  presents  a  formidable
challenge for the development of antiviral treatments because
of the diverse viruses responsible for this disease. One common
factor shared by all the common cold viruses is that they must
somehow  reach  their  specific  host  cell  receptor  by  moving
down through a relatively great depth of respiratory fluid and
mucus  and  that  they  must  achieve  this  journey  without  any
means  of  self-propulsion.  This  article  will  discuss  how
common  cold  viruses  may  utilise  their  electrical  charge  to
reach  the  host  cell  surface  and  how  this  mechanism  may  be
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confounded  by  large  polyanionic  molecules  such  as  iota-
carrageenan.
2.  IMPORTANCE  OF  ELECTRICAL  CHARGE  ON
VIRUSES AND CELLS
Respiratory  viruses  are  trapped  and  washed  away  in  a
protective  layer  of  respiratory  mucus  as  part  of  the  normal
respiratory defence against infection by mucociliary clearance.
Respiratory mucus and fluid are some 10 micrometres in depth
[3] and compared to the size of respiratory viruses such as a
rhinovirus,  which  is  some  30  nanometres  in  size  [4].  This
presents  a  formidable  barrier  to  infection.  In  order  to  infect
cells lining-the respiratory tract,  the viruses must contact the
host cell and interact with a receptor that triggers penetration of
the  host  cell  membrane.  The  initial  movement  of  the  virus
towards  the  cell  is  dependent  on  Brownian  motion,  which
knocks the virus in random directions, and eventually, the virus
comes close enough to the cell to be attracted to the cell surface
by other factors such as the electrostatic attraction of the virus
to  large  charged  molecules  on  the  surface  of  the  cell  [5,  6].
Naked respiratory viruses such as rhinoviruses must attach to a
specific  receptor  on  epithelial  cells  in  order  to  uncoat  and
invade  cells,  whereas  many  enveloped  viruses  fuse  with
cellular membranes in order to penetrate the cell [7]. The initial
encounter between a virus and its host cell is not with a virus-
specific  receptor  but  with  the  ubiquitous  glycoprotein
attachment  factors  such  as  Heparan  Sulphate  Proteoglycans
(HSP)  on  the  cell  surface  [8].  In  general,  the  surface  of
mammalian cells presents a negative electric field due to the
Fig.  (1).  Structure  of  heparan  sulphate,  illustrating  the  disaccharide
repeating units (dimers) with two negatively charged sulphate groups.
(-VE means negatively charged).
ubiquitous HSP molecules on the cell surface and this electrical
property of cells can be utilised by positively charged viruses
to  direct  the  virus  towards  the  cell  surface  and closer  to  any
specific  receptor  on  the  cell  surface.  Heparan  Sulphate
Proteoglycans (HSP) are found on the cell surface of all tissues
and  in  the  extracellular  matrix  where  they  interact  with
numerous  ligands  such  as  cytokines,  chemokines,  enzymes,
and growth factors [9, 10]. HSP are glycoproteins containing
one or more covalently attached Heparan Sulphate chains (HS)
with 40-300 sugar residues [10]. The HS chain is made up of
linked dimers of sugar molecules, as illustrated in Fig. (1), and
the sulphate and other groups along the chain give HS a high
electronegative  charge  to  make  it  one  of  the  most  highly
negatively  charged  polymers  in  nature  [10].
3. CARRAGEENAN
Carrageenan is a general term used to describe sulphated
polysaccharides extracted from edible seaweeds. Carrageenan
is widely used in the food industry for its thickening and gel-
like properties in food products such as ice cream and sauces. It
is  also  used  to  formulate  syrups,  and  in  cosmetics  and
processed  meat  [11].  The  in  vitro  antiviral  activity  of
carrageenan was first described in 1958 when carrageenan was
shown  to  exert  a  marked  inhibitory  effect  on  the  growth  of
influenza  B  virus  and  mumps  virus  in  embryonated  chicken
eggs  [12].  Since  the  discovery  of  the  antiviral  activity  of
carrageenan  in  1958  carrageenan  has  been  shown to  have  in
vitro  antiviral  activity  for  a  wide  range  of  viruses  such  as
hepatitis  A  virus  [13],  herpes  simplex  virus  [14],  rhinovirus
[15], papillomavirus [16], dengue virus [17], various enveloped
viruses such as cytomegalovirus, vesicular stomatitis virus and
human immunodeficiency virus [18], porcine reproductive and
respiratory syndrome virus [19] and influenza A virus [20].
The  term  carrageenan  covers  a  range  of  sulphated
polysaccharides  and  oligosaccharides,  but  the  three
commercially  important  carrageenans  are  iota-,  kappa-  and
lambda-  carrageenans.  These  carrageenans  are  composed  of
disaccharide repeating units (dimers), with the kappa, iota and
lambda dimers having one, two and three sulphate ester groups
respectively  resulting  in  correspondent  calculated  sulphate
contents of 20%, 33% and 41% (w/w) [21]. Iota-carrageenan
applied as a nasal spray has been shown in human clinical trials
to have efficacy as an early treatment for the common cold and
to have antiviral  activity against  common cold and influenza
viruses [15, 22 - 25].
4. CARRAGEENAN AS AN ANTIVIRAL FOR HUMAN
VIRAL DISEASE
The  antiviral  activity  of  a  seaweed  extract  containing
carrageenan was first discovered by chance in 1958 by Gerber
et al. [12] at the Squibb Institute for Medical Research in New
Jersey,  USA.  The  investigators  were  searching  for  new
antiviral  compounds  using  the  chick  embryo  as  a  screening
model, and influenza B and mumps virus as test viruses. The
results  of  the  studies  were  erratic  as  they  were  using  0.25%
agar  as  a  vehicle  for  the  viruses  and  they  suspected  that  the
vehicle  had  more  antiviral  activity  than  any  of  the  antivirals
they were testing. They went on to study the antiviral effects of
carrageenan extracted from seaweeds (agar) and demonstrated
that  the  carrageenan  had  a  marked  inhibitory  effect  on  the
replication  of  influenza  B  and  mumps  viruses.  They
demonstrated that significant protection against fatal influenza
B infection of the chick embryo was obtained even when the
treatment with carrageenan was delayed for as long as 24 hours
after  the  inoculation  with  the  virus  [12].  It  is  surprising  that
after  the  clear  demonstration  of  in  vitro  antiviral  activity  of
carrageenan  in  1958,  there  were  no  immediate  follow-up
animal or human studies to develop an antiviral treatment for
human use and it  was some 50 years later before any human
treatment was investigated.
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Carrageenan  was  shown  in  the  years  after  1958  to  have
antiviral  activity against a wide range of viruses in vitro  and
there  was  increasing  interest  in  the  use  of  carrageenan  as  a
treatment for HPV from 2006 when carrageenan used in sexual
lubricants  and lubricated condoms was shown to be a  potent
inhibitor of HPV infection in vitro [16]. This led to proposals
for a human clinical trial in 2010 and the interim analysis of
this trial suggests that using a carrageenan-based lubricant gel
can reduce the risk of genital HPV infections in women [26].
In  2007 at  around the  same time that  clinical  trials  were
being discussed based on the effects of carrageenan on HPV,
interest  was  also  developing  at  Marinomed  Biotech  AG
(Marinomed), a company in Vienna Austria, on a clinical trial
on  the  efficacy  of  carrageenan  as  a  nasal  spray  for  the  early
treatment  of  a  common  cold.  In  vitro  studies  in  Austria
conducted by Marinomed, demonstrated that iota-carrageenan
was a potent inhibitor of rhinovirus infection of cultured HeLa
cells  [15].  Following the  positive  results  of  in  vitro  antiviral
studies  on  rhinovirus,  Marinomed  contacted  the  author  to
conduct  the  first  clinical  trial  on  the  antiviral  effects  of
carrageenan  at  the  Common  Cold  Centre  based  in  Cardiff
University, UK. The results of this pilot study were published
in 2010 [22] and despite the small number of patients involved
in the pilot study (17 in the carrageenan treated group and 18 in
the placebo group), the study reported a significant reduction in
the symptoms of the common cold (p = 0.046) and a reduction
in  mixed  viral  load  in  nasal  lavage  (p  =  0.009)  when  iota-
carrageenan as an intranasal spray (0.12% solution in saline)
was  used  as  an  early  treatment  of  common  cold  (within  48
hours of symptom onset) [22]. The results of this pilot study on
iota-carrageenan nasal spray are now supported by three larger
studies  on  the  early  treatment  of  common  cold  involving
hundreds  of  adults  and  children  [24,  25,  27].
5.  PROPOSED  MECHANISM  OF  ACTION  OF  IOTA-
CARRAGEENAN AS AN ANTIVIRAL
Iota-carrageenan is a highly negatively charged long-chain
polysaccharide  made  up  of  dimers  similar  in  structure  and
electrical charge to HS as illustrated in Fig. (2). Both HS and
iota-carrageenan  have  negatively  charged  sulphate  groups
along the chain and these provide most of the dense electrical
charge of the polyanionic molecules. Iota-carrageenan mimics
the HS that the virus is first attracted to on the surface of the
cell and can, therefore, trap the virus and prevent infection, as
illustrated in Fig. (3a and 3b ). In the early stage of infection,
newly  released  viruses  infect  adjacent  epithelial  cells  and
magnify the infection and increase the viral titre as illustrated
in  Fig.  (3a).  When  iota-carrageenan  is  present  in  the  early
stages of infection, it acts like airway mucus to trap viruses, as
the mucins in airway mucus have a high sialic acid content and
this together with the high sulphate content results in a strongly
negatively  charged  surface  which  may  attract  any  positively
charged surface of an airway virus [28]. The long, negatively
charged iota-carrageenan molecule attracts and traps the newly
released  positively  charged  viruses  and  prevents  them  from
infecting  adjacent  nasal  epithelial  cells,  as  illustrated  in  Fig.
(3b).  The  iota-carrageenan  and  trapped  viruses  will  be
transported by mucociliary clearance to the nasopharynx and
then swallowed, and the viruses will be destroyed in the acid
environment of the stomach.
The  antiviral  efficacy  of  polyanionic  molecules  such  as
iota-carrageenan is dependent on early intervention at the first
sign  of  symptoms,  in  order  to  prevent  the  spread  and
magnification of  infection along the  respiratory mucosa,  and
that is why nasal spray treatments, as discussed below, are used
in clinical trials within 24-48 hours of the onset of symptoms.
6.  WHY  IOTA-CARRAGEENAN  IS  AN  IDEAL
TREATMENT FOR THE COMMON COLD
Iota-carrageenan nasal spray is an ideal early treatment for
the  common  cold  because  of  several  characteristics;  safety,
tolerability, lack of interaction with any other medications, and
a  non-specific  antiviral  action  against  different  groups  of
viruses.
Fig.  (2).  Structure  of  iota-carrageenan,  illustrating  the  disaccharide
repeating units (dimers) with two negatively charged sulphate groups.
(-VE means negatively charged).
6.1. Safety
Common  cold  is  the  most  common  diseases  of  mankind
and  is  especially  common  in  infants  and  children.  Any
treatment for common cold must have a good safety profile as
the benefits of treating a self-limiting disease of short duration
must  be  balanced  against  any  risks  posed  by  the  treatment.
Iota-carrageenan is a large polysaccharide molecule which is
neither absorbed from the respiratory tract nor metabolised. It
works against respiratory viruses by its physical properties and
electrical charge, and as a nasal spray is licensed for use as a
medical  device  rather  than  as  a  medicine.  Iota-carrageenan
does not have any pharmacological properties and, therefore,
does  not  have  any  toxicology  or  known  side  effects  on
treatment. The safety of iota-carrageenan is demonstrated from
the  results  of  four  placebo-controlled  clinical  trials  which
reported that there were no significant differences in adverse
events  between  the  verum  and  placebo-treated  groups  and
those  adverse  events  were  mainly  related  to  symptoms  of
respiratory viral infection [22, 24, 25, 27]. There are no long-
term safety studies on the nasal spray, but it has been marketed
across Asia and Europe for several years with no indication of
any  safety  issues.  Carrageenans,  including  iota-carrageenan,
are  widely  used  in  the  food,  pharmaceutical  and  cosmetic
industries and are Generally Recognised As Safe (GRAS) [29].
The safety of iota-carrageenan administered as a nasal spray or
nebulised (0.12%) has been studied in rabbits and rats and no
absorption of the carrageenan was reported and the data did not
show any local intolerance or toxicity of the iota-carrageenan
[29]. It is important to note that the dose of iota-carrageenan
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given intranasally is very small compared to the large amounts
of carrageenans that may be ingested in many foods, and the
controversy that surrounds the safety of carrageenans in foods
[30] does not apply to the topical use of a nasal spray.
6.2. Tolerability
Common  cold  is  an  acute  disease  that  can  be  treated  by
self-medication at home. Any treatment for common cold with
significant side effects will not be tolerated by the patient. Iota-
carrageenan nasal  spray does  not  have any side  effects  apart
from those associated with the use of a nasal spray and it does
not cause any nasal irritation or nasal sensation.
6.3. Interaction with Other Medicines and Treatment
Iota-carrageenan works as a medical device by its physical
properties and therefore does not have any known interaction
with any other concomitant treatments for the common cold or
any other disease. If patients are using other nasal treatments
such as saline, corticosteroids, bronchodilators, etc., it is best to
use the iota-carrageenan nasal spray at least an hour before or
after  the  other  treatment,  in  order  to  avoid  diluting  the
treatment  and  any  interaction.
6.4.  Non-Specific  Antiviral  Against  a  Wide  Range  of
Viruses
Common cold is caused by a wide range of RNA and DNA
respiratory  viruses  and  any  treatment  that  works  specifically
against one type of virus is unlikely to be effective in treating
the majority of cases of the common cold. In vitro and in vivo
studies  have  shown  that  iota-carrageenan  has  efficacy  in
reducing  the  viral  load  of  a  wide  range  of  RNA  and  DNA
based  viruses  such  as  rhinoviruses  [15]  hepatitis  A  [13]  and
influenza viruses [23].
6.5.  Efficacy  of  Iota-Carrageenan  Nasal  Spray  as  a
Treatment for the Common Cold
Iota-carrageenan nasal spray has been shown to reduce the
titres  of  respiratory  viruses  and  to  reduce  the  severity  of
symptoms  in  placebo-controlled  clinical  trials,  including
children and adults [22, 24, 25, 27]. A summary of some of the
results of clinical trials is illustrated in Table 1.
Fig. (3a). In the early stage of infection, newly released viruses infect
adjacent  epithelial  cells  and  magnify  the  infection  and  increase  the
viral titre.
Fig. (3b). Mechanism of action of iota-carrageenan as an antiviral for
the treatment  of  a  common cold.  The long,  negatively  charged iota-
carrageenan molecule attracts and traps the newly released positively
charged  viruses  and  prevents  them  from  infecting  adjacent  nasal
epithelial  cells.  The  iota-carrageenan  and  trapped  viruses  will  be
transported  by  mucociliary  clearance  to  the  nasopharynx  and  then
swallowed, and the viruses will be destroyed in the acid environment
of the stomach. (-VE means negatively charged).
Table 1. Summary of clinical trials on the iota-carrageenan nasal spray as a treatment for the common cold.
Publication Patients Treatment Antiviral Symptomatology
Eccles et al. (2010)
A double-blind placebo-
controlled trial [22]
n = 35 Adults
mean age 19.6
years
0.12% iota-carrageenan
nasal spray, 3 times a day
for four days
Nasal lavage was analyzed by real-time
RT-PCR for the presence of viral
genomes. Viral load in the respiratory
virus-positive patients increased by almost
sixfold, whereas it decreased by 92% in
the iota-carrageenan treatment group (p <
0.009).
Carrageenan treated group had a
reduction in total symptom
scores between days 2-4 of the
trial (p=0.046)
Fazekas et al. (2012)
Double-blind placebo-
controlled trial [24]
n = 153
children aged
between 1-18
years, mean
age 5 years
0.12% iota-carrageenan
nasal spray, 3 times a day
for seven days
Topical application of the iota-carrageenan
spray reduced
viral loads in nasal secretions to a
significantly higher
degree than placebo after 3 to 5 days of
treatment
(p = 0.026
A non-significant reduction in
total symptom scores between
days 2-7 of trial
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Publication Patients Treatment Antiviral Symptomatology
Ludwig et al. (2013)
Double-blind placebo-
controlled trial [27]
n = 211 adults
mean age 33
years
0.12% iota-carrageenan
nasal spray, 3 times a day
for seven days
Viral titers in nasal fluids showed a
significantly greater decrease in
carrageenan treated patients in the
intention-to-treat population (p = 0.024)
and in the per-protocol population (p =
0.018) between days 1 and 3/4.
Significant reduction in total
symptom scores in later days of
cold (p=0.048)
Eccles et al. (2015)
Double-blind placebo-
controlled trial [25]
n = 200 adults
mean age 20
years
0.12% iota-carrageenan
nasal spray, 4 times a day
for four days
Non-significant trend for a reduction in
viral titres in the iota-carrageenan group
compared to the placebo group.
Significant reduction in total
symptom scores between days
2-4 of the trial (p = 0.0364)
Eccles  et  al.  (2010)  conducted  the  first  double-blind,
randomised,  placebo-controlled  clinical  trial  on  an  iota-
carrageenan (0.12%) nasal spray in Cardiff, United Kingdom.
The  study  was  a  small  study  involving  35  adults  (mean  age
19.6  years)  with  early  symptoms  of  the  common  cold  (<48
hours onset of symptoms). The nasal spray was administered
into each nasal passage three times a day for four days. Nasal
lavage was obtained on day 1 (before treatment) and day 3 or 4
(during  treatment).  The  results  reported  that  the  pre-defined
primary efficacy variable showed a significant difference (p <
0.046) between placebo and iota-carrageenan treatment groups
for the total symptom score (day 2-4) with the iota-carrageenan
treatment  group  having  lower  symptom scores  than  placebo.
Nasal  lavage  was  analyzed  by  real-time  RT-PCR  for  the
presence of viral genomes. Viral load in the respiratory virus-
positive  patients  increased  by  almost  sixfold,  whereas  it
decreased by 92% in the iota-carrageenan treatment group (p <
0.009).
Fazekas  et  al.  (2012)  conducted  a  double-blind,
randomised, placebo-controlled trial similar to the design of the
trial  conducted by Eccles  et  al.  (2010)  on 153 children aged
between 1-18 years (mean age 5 years) with early symptoms of
the common cold (<36 hours onset  of  symptoms) in Vienna,
Austria.  The  nasal  spray  was  administered  into  each  nasal
passage three times a day for seven days. The primary efficacy
variable  was the difference in  total  symptom scores  between
days  2-7,  but  this  did  not  reach  any  statistically  significant
difference  between  treatment  groups,  perhaps  because  the
children and their parents had difficulty in assessing symptom
scores due to the young age of the children. However, the trial
did  report  a  significant  reduction  in  viral  load  (p  =  0.026),
reduced time to clearance of the disease symptoms (7.6 in the
iota-carrageenan  treatment  group  versus  9.4  days  in  the
placebo  group,  p  =  0.038).
Ludwig  et  al.  (2013)  conducted  a  double-blind,
randomised, placebo-controlled trial on 211 patients (mean age
33 years) with early symptoms of the common cold (< 48 hours
onset  of  symptoms) in  Vienna,  Austria.  The nasal  spray was
administered  into  each  nasal  passage  three  times  a  day  for
seven  days.  In  patients  showing  a  laboratory-confirmed cold
virus  infection  and  adherence  to  the  protocol,  alleviation  of
symptoms  was  2.1  days  faster  in  the  carrageenan  group  in
comparison to placebo (p = 0.037). Viral titers in nasal fluids
showed a significantly greater decrease in carrageenan treated
patients in the intention-to-treat population (p = 0.024) and in
the  per-protocol  population  (p  =  0.018)  between  days  1  and
3/4.
Eccles et al. (2015) conducted a double-blind, randomised,
placebo-controlled  trial  on  200  patients  (mean  age  20  years)
with early symptoms of the common cold (< 48 hours onset of
symptoms) in Cardiff, United Kingdom. The nasal spray was
administered  into  each  nasal  passage  four  times  a  day  for  a
mandatory four days, with an option to continue treatment up
to a maximum duration of 10 days. The primary end-point was
the  difference  between  treatment  groups  for  total  symptom
scores  between  days  2-4  and  this  reached  statistical
significance (p = 0.0364) when one patient was excluded from
analysis  due  to  probably  misunderstanding  the  symptom
scoring.  Only  45%  of  the  patients  tested  positive  for  a
respiratory  virus,  but  in  these  patients,  there  was  a  non-
significant  trend  for  a  reduction  in  viral  titres  in  the  iota-
carrageenan  group  compared  to  the  placebo  group.
Clinical  trials  on  patients  with  the  common  cold  are
difficult because of the acute nature of the disease and because
patients  often  self-medicate  or  present  too  late  for  treatment
and must be excluded from entry into trials that are studying
the early treatment of a common cold. Like any clinical trial,
the four clinical trials on iota-carrageenan can be criticised as
being either a small pilot study [22], not achieving statistical
significance  on  the  primary  outcome  measure  [25],  or  only
showing effects  on viral  titre  and not  on symptoms [24,  27].
But when the four trials are considered together, they provide
evidence that an iota-carrageenan nasal spray can reduce viral
titres, and also reduce symptom severity in common cold.
7.  SOURCE  OF  IOTA-CARRAGEENAN  USED  IN
NASAL SPRAYS
The iota-carrageenan used in nasal sprays for the treatment
of  common  cold  is  pharma  grade  iota-carrageenan,  Gelcarin
379NF obtained from DuPont. This source of iota-carrageenan
is mainly produced from the seaweed Echeuma denticulatum,
which is sometimes named Echeuma spinosum.  The polymer
contains mainly >90% iota-carrageenan and, to a much lesser
extent  <10%  kappa-carrageenan  but  does  not  contain  any
lambda-carrageenan  [31].
CONCLUSION
Common  cold  is  caused  by  a  wide  range  of  respiratory
viruses  and  any  antiviral  treatment  for  this  common  disease
must work on some mechanism of viral activity that is common
to all of these viruses. All respiratory viruses must pass through
the physical barrier of mucus and respiratory fluid in order to
reach the cell surface and this article proposes that the viruses
may utilise their positive electrical charge in order to reach the
negatively charged cell surface. Polyanionic molecules such as
iota-carrageenan may present a way of trapping the viruses as
(Table 1) cont.....
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they  move  towards  the  surface  of  the  cell.  The  lack  of  any
pharmacological or toxicological activity in large polyanionic
molecules  such  as  iota-carrageenan  due  to  their  lack  of
absorption or metabolism makes them a safe topical antiviral
treatment. The efficacy and safety of an iota-carrageenan nasal
spray have been studied in four clinical trials to date, and the
results  of  these  trials  provide  some  support  the  efficacy  and
safety  of  iota-carrageenan as  an  early  treatment  for  common
cold.  Further  research  is  needed  on  polyanionic  compounds
like iota-carrageenan for the treatment of common cold.
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Relevant  publications  were  found  by  searching  PubMed
during  July2018-January  2020.  The  main  search  terms  were
“carrageenan”,  “iota-carrageenan”  “common  cold”,  “URTI”,
“heparan  sulphate”.  The  bibliographies  of  key  articles  were
used to identify other relevant articles. Key articles were used
in cited reference searches on the Web of Science database.
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